Trial Profile
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs ABSK 091 (Primary) ; Durvalumab (Primary) ; Erlotinib (Primary) ; Inbakicept (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Palbociclib (Primary) ; Pembrolizumab (Primary) ; Rilotumumab (Primary) ; Talazoparib (Primary) ; Taselisib (Primary) ; Tremelimumab (Primary) ; Docetaxel; Gemcitabine; Pemetrexed; Ramucirumab
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Biomarker; Therapeutic Use
- Acronyms Lung-MAP
- 07 Sep 2023 Results presented in a Strata Oncology media release.
- 07 Sep 2023 According to a Strata Oncology media release, data showing its proprietary biomarker algorithm, Immunotherapy Response Score (IRS) from this study will be presented at the 2023 World Conference on Lung Cancer.
- 07 Jun 2022 Results evaluating if factors associated with better prognoses with ICB from single-agent versus combined targeting PD-1/CTLA-4 and evaluating if any differentiated between the treatments, by deriving immunogenomic profiling of tissue specimens, presented at the 58th Annual Meeting of the American Society of Clinical Oncology